Back grey_arrow_rt.gif
 
 
Abbott's New HCV Study: ABT450+ABT072+Ribavirin
 
 
  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
This study is currently recruiting participants.
Verified by Abbott, October 2010
 
Official Title: An Open Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Na•ve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
 
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org